Search
Evotec SE
EVOAdd to Watchlist
1.979USD
+0.069+3.62%
Close 07-31 16:00（ET）Quotes delayed by 15 min
703.26MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Evotec SE is 6.67, ranking 325 out of 385 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 7.00 and a low of 3.00.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
2.800
Target Price
+46.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Evotec SE
EVO
3
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Evotec SE's expected revenue for the next quarter?
Evotec SE's expected revenue is 165.41M.
What is Evotec SE's price target?
Analysts forecast that Evotec SE's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 3.00.
How have Evotec SEEVO's recent earnings per share performed?
The market expectation was USD -0.40, while Evotec SEEVO's earnings per share (EPS) for the previous quarter was USD 0.05. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for Evotec SE?
Based on the ratings of Evotec SE's stock from 3 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.